Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard

  • Hong T
  • Kachnic L
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Combined-modality therapy consisting of surgery, radiotherapy, and chemotherapy is the recommended management strategy for patients with stage II and III rectal cancer. Adjuvant radiotherapy has been used to improve upon the historically high pelvic recurrence rates. Both preoperative and postoperative radiation treatment strategies have been extensively studied. However, the recently published 5-year results of the randomized German CAO/ARO/AIO 94 trial of preoperative vs. postoperative chemoradiotherapy support a standard preoperative treatment approach. Randomized trials have also demonstrated that the addition of chemotherapy to preoperative radiotherapy significantly enhances tumor downstaging, pathologic response, and local control over radiation alone. The role of concurrent preoperative chemoradiotherapy, the investigation of novel systemic and biologic agents (capecitabine, oxaliplatin, irinotecan, bevacizumab, and cetuximab) and other key issues in the preoperative treatment of localized rectal cancer are discussed.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • PMID: 19262719

Authors

  • T S Hong

  • L A Kachnic

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free